Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

Saskia L.M. Gooskens; Arnold P. Oranje; Leon N.A. Van Adrichem; Flora B. De Waard-Van Der Spek; Jan C. Den Hollander; Cees P. Van De Ven; Marry M. Van Den Heuvel-Eibrink

doi:10.1002/pbc.22494

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

Saskia L.M. Gooskens
, Arnold P. Oranje
, Leon N.A. Van Adrichem
, Flora B. De Waard-Van Der Spek
, Jan C. Den Hollander
, Cees P. Van De Ven
, Marry M. Van Den Heuvel-Eibrink

Research output: Contribution to journal › Article › peer-review

60 Citations (Scopus)

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome.

Original language	English
Pages (from-to)	369-373
Number of pages	5
Journal	Pediatric Blood and Cancer
Volume	55
Issue number	2
DOIs	https://doi.org/10.1002/pbc.22494
Publication status	Published - Aug 2010
Externally published	Yes

Keywords

Children
Dermatofibrosarcoma protuberans
Imatinib
Treatment

Access to Document

10.1002/pbc.22494

Cite this

@article{f4e88d66804a4daca81d6682d1796bb9,

title = "Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)",

abstract = "Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome.",

keywords = "Children, Dermatofibrosarcoma protuberans, Imatinib, Treatment",

author = "Gooskens, \{Saskia L.M.\} and Oranje, \{Arnold P.\} and \{Van Adrichem\}, \{Leon N.A.\} and \{De Waard-Van Der Spek\}, \{Flora B.\} and \{Den Hollander\}, \{Jan C.\} and \{Van De Ven\}, \{Cees P.\} and \{Van Den Heuvel-Eibrink\}, \{Marry M.\}",

year = "2010",

month = aug,

doi = "10.1002/pbc.22494",

language = "English",

volume = "55",

pages = "369--373",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

AU - Gooskens, Saskia L.M.

AU - Oranje, Arnold P.

AU - Van Adrichem, Leon N.A.

AU - De Waard-Van Der Spek, Flora B.

AU - Den Hollander, Jan C.

AU - Van De Ven, Cees P.

AU - Van Den Heuvel-Eibrink, Marry M.

PY - 2010/8

Y1 - 2010/8

N2 - Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome.

AB - Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor β (PDGFβ) with the collagen type 1α1 (COL1α1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome.

KW - Children

KW - Dermatofibrosarcoma protuberans

KW - Imatinib

KW - Treatment

UR - https://www.scopus.com/pages/publications/77955104531

U2 - 10.1002/pbc.22494

DO - 10.1002/pbc.22494

M3 - Article

C2 - 20582941

AN - SCOPUS:77955104531

SN - 1545-5009

VL - 55

SP - 369

EP - 373

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

ER -

Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

Abstract

Keywords

Access to Document

Fingerprint

Cite this